Inhibitory neurotransmission plays an important role in controlling excitability within nociceptive circuits of the spinal cord dorsal horn. Loss of inhibitory signalling is thought to contribute to the development of pathological pain. Preclinical studies suggest that increasing inhibitory glycinergic signalling is a good therapeutic strategy for treating pain. One approach to increase synaptic glycine is to inhibit the activity of the glycine transporter 2 (GlyT2) on inhibitory nerve terminals. These transporters are involved in regulating glycine concentrations and recycling glycine into presynaptic terminals. Inhibiting activity of GlyT2 increases synaptic glycine, which decreases excitability in nociceptive circuits and provides analgesia in neuropathic and inflammatory pain models.
Introduction
Regulation of sensory processing in the spinal cord is mediated through the fast inhibitory neurotransmitters glycine and GABA (Zeilhofer et al., 2012) . These inhibitory neurotransmitters play important roles in limiting excitability in the nociceptive circuits of the dorsal horn, and when the receptors of these neurotransmitters are antagonized in vivo, this leads to the symptoms of pathological pain (Yaksh, 1989) . Studies from our group and others using animal models of neuropathic pain have shown that loss of inhibitory GABAergic and glycinergic neurotransmission, or disinhibition, occurs in the dorsal horn in peripheral nerve injury (Yaksh, 1989; Sivilotti and Woolf, 1994; Loomis, 1995, 1996; Imlach et al., 2016) . The crucial role of glycine signalling in the control of nociceptive transmission in the dorsal horn was recently demonstrated in studies where glycinergic neurons were either ablated or activated in mice, which caused pain and analgesia respectively (Foster et al., 2015) . Since glycinergic neurotransmission has such a profound influence on whether or not nociceptive signals are transmitted to the brain, this system is an attractive target for pain therapeutic development (Imlach, 2017) .
Concentrations of glycine around inhibitory and excitatory synapses in the CNS are regulated by the glycine transporters 1 and 2 (GlyT1 and GlyT2), which are part of the sodiumdependent solute carrier family 6 transporters. GlyT1 is expressed by astrocytes at inhibitory and excitatory synapses and is also in a subpopulation of glutamatergic terminals, while GlyT2 expression is restricted to the presynaptic terminals of inhibitory glycinergic neurons (Zeilhofer et al., 2005) . GlyT2 plays important roles in regulating synaptic glycine concentrations and recycling glycine back to the presynaptic terminals to maintain sufficient stores of glycine-containing vesicles (Zafra et al., 1995) . Many of the inhibitory interneurons that regulate nociceptive signalling in the dorsal horn are located in lamina III, an area where GlyT2 is highly expressed (Zeilhofer et al., 2012) . GlyT2 more effectively reduces glycine concentration compared with GlyT1 and is able to reduce synaptic glycine to the low nanomolar range, preventing low-level glycine receptor activation (Supplisson and Roux, 2002) . This fine control of synaptic glycine levels by GlyT2 suggests that inhibition of this transporter's activity would reduce clearance of synaptic glycine and increase basal inhibitory neurotransmission, which in turn would reduce nociceptive signalling in the dorsal horn. However, the balance between complete and partial inhibition of GlyT2 is also an important factor, as too much inhibition reduces synaptic vesicle loading, thus preventing synaptic glycine release (Vandenberg et al., 2014) . The effect of complete inhibition has been observed in GlyT2 knockout mice that suffer from severe motor deficiencies by the second postnatal week due to loss of glycine at motor neuron synapses (Gomeza et al., 2003) . Conversely, partial knockdown of the GlyT2 gene using siRNAs results in a normal motor phenotype, and the reduction in GlyT2 activity corresponds with reduced allodynia scores in a mouse model of neuropathic pain (Morita et al., 2008) , suggesting that partial inhibitors of GlyT2 may avoid side effects caused by loss of synaptic glycine.
Studies investigating the therapeutic potential of the early GlyT2 inhibitors, ALX1393 and ORG25543, report that they are analgesic when administered i.v. in a mouse model of neuropathic pain (Morita et al., 2008) . However, ALX1393 also inhibits GlyT1 at higher concentrations, which may exacerbate pain symptoms by increasing glycine at excitatory NMDA receptors and increasing spinal sensitization (Mingorance-Le Meur et al., 2013) . The GlyT2 inhibitor ORG25543 has similar antinociceptive effects to ALX1393 in in vivo pain models and has been found to increase glycinergic tonic currents and evoked inhibitory postsynaptic current (eIPSC) decay time in spinal cord slices (Bradaia et al., 2004) . However, ORG25543 is an irreversible inhibitor of GlyT2, and following an initial increase in glycinergic activity, it causes a significant reduction in glycinergic eIPSCs in vitro suggesting that presynaptic glycine vesicle recycling is reduced to a level that does not support synaptic signalling (Gomeza et al., 2003) . In a study by Wiles et al. (2006) , the endocannabinoid N-arachydonoylglycine (NAG) was shown to selectively and reversibly inhibit GlyT2 over GlyT1 and the GABA transporter GAT1. NAG has also been shown to act as an allosteric modulator of glycine receptors, with potentiation of α1 glycine receptors and inhibition of the α2 and α3 subtypes (Yévenes and Zeilhofer, 2011) . NAG is found in high concentrations in the spinal cord and reduces pain in rodent inflammatory and neuropathic pain models through a mechanism that is independent of cannabinoid receptor activation (Succar et al., 2007; Vuong et al., 2008) .
Recently, a number of lipid inhibitors including oleoyl-L-carnitine (OL-Carn; C18 cis ω9 L-carnitine) and N-oleoylglycine (NOGly; C18 cis ω9 glycine) that are based on the endogenous GlyT2 inhibitor NAG have been tested as GlyT2 inhibitors (Carland et al., 2013) . OL-Carn and NOGly have different head groups, but both have a C18 (oleoyl) tail (Table 1) . This difference in head group results in greater potency of OL-Carn at inhibiting GlyT2 expressed in oocytes but exhibits less reversibility compared with NAG (Carland et al., 2013) . Lipid compounds with variations in the tail length have also been investigated as GlyT2 inhibitors in oocyte studies and C18 have been found to have the highest affinity. Double bonds in the lipid tail also have an influence on efficacy with C18:0 and C18:2 derivatives showing less efficacy than the C18:1 derivative. In this study, we compared the effects of OL-Carn and NOGly with structurally related compounds in order to investigate how differences in head and tail groups affect glycinergic transmission in the spinal cord. Other compounds used in this study include compounds with different placements of the double bond (C18 cis ω8 glycine) and with shortened tail length (C16 cis ω3 glycine) (Table 1) . These compounds may provide more specific and reversible inhibition of GlyT2 and may lead to more effective therapeutics for targeting glycine transport to treat pathological pain.
Methods

Animals
Sprague-Dawley rats were housed in groups of 2-4, in individually ventilated cages with access to standard rat chow and 12 h light-dark cycles. Rats were delivered from the supplier weekly and were not randomized as there were no procedures or experiments performed prior to spinal cord extraction. All animal experiments were performed in accordance with the Animal Ethics Committee guidelines of the University of Sydney and Monash University and were approved by the respective committees (University of Sydney animal ethics approval number: 2015/803 and Monash University animal ethics approval number MARP-2017-062). The animals used in this study were of the same age, weight and gender. Male rats were used to allow consistency with other studies. Animals were sourced from the Animal Resources Centre, Western Australia or the Monash Animal Research Platform. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Animal numbers were reduced as much as possible without compromising the amount of data points.
Preparation of spinal cord slices
Adult male Sprague-Dawley rats (6-8 weeks at the time of slice preparation,~180-260 g) (n = 49 rats) were anaesthetized with isoflurane and decapitated, and the lumbar region of the spinal cord was removed. Parasagittal slices (340 μm thick) of spinal cord were cut on a vibratome (Leica VT 1200s, Leica Microsystems Pty Ltd, Melbourne VIC, Australia) in oxygenated ice-cold sucrose-based artificial CSF (ACSF) that contained (mM) 100 sucrose, 63 NaCl, 2.5 KCl, 1.2 NaH 2 PO 4 , 1.2 MgCl 2 , 25 glucose and 25 NaHCO 3 . Slices were transferred to a submerged chamber containing NMDG-based recovery ACSF for 15 min at 34°C, equilibrated with 95% O 2 and 5% CO 2 and composed of (mM) 93 NMDG, 2.5 KCl, 1.2 NaH 2 PO 4 , 30 NaHCO 3 , 20 HEPES, 25 glucose, 5 Na ascorbate, 2 thiourea, 3 Na pyruvate, 10 MgSO 4 and 0.5 CaCl 2 and adjusted to pH 7.4 with HCl. Following the recovery incubation, slices were transferred to normal oxygenated ACSF where they were allowed to recover for 1 h at 34°C and then maintained at room temperature prior to transfer to the recording chamber. Normal ACSF had the following composition (mM): 125 NaCl, 2.5 KCl, 1.25 NaH 2 PO 4 , 1.2 MgCl 2 , 2.5 CaCl 2 , 25 glucose and 11 NaHCO 3 and was equilibrated with 95% O 2 and 5% CO 2 .
Electrophysiology
Slices were transferred to a recording chamber and superfused continuously at 2 mL·min À1 with normal ACSF that had been equilibrated with 95% O 2 and 5% CO 2 and maintained at 34°C with an inline heater and monitored by a thermister in the slice chamber. Dodt-contrast optics was used to identify lamina II neurons in the translucent substantia gelatinosa Mostyn et al. (2017) . 2 IC 50 data show inhibition of 30 μM glycine transport by GlyT2 and GlyT1, expressed in Xenopus laevis oocytes from Carland et al. (2013) .
layer of the superficial dorsal horn. A Cs + -based internal solution, which should minimize postsynaptic effects, was used to record electrically eIPSCs or NMDA-evoked excitatory postsynaptic currents (eEPSCs) and contained (mM) 140 CsCl, 10 EGTA, 5 HEPES, 2 CaCl 2 , 2 MgATP, 0.3 NaGTP, 5 QX-314.Cl, 2 (osmol 285-295 mosmol·L À1 ). QX-314 was used in patch electrodes to prevent action potential firing when recording NMDA receptor-mediated currents, as action potential activity can prevent detection of synaptic currents, particularly at the depolarized potentials required for NMDA receptor-mediated currents. We did not observe loss of NMDA receptor-mediated currents with QX-314. Patch electrodes had resistances between 3 and 5 MΩ. Synaptic currents were measured in whole-cell voltage clamp (À70 mV for eIPSCs or À40 mV for eEPSCs, not corrected for a liquid junction potential of 4 mV) from lamina II cells. Bipolar tungsten electrodes placed in the inner laminae (lamina III region) were used to elicit eIPSCs using a stimulus strength sufficient to evoke reliable eIPSCs. Neurons ventral to lamina II, in regions that are known to contain glycinergic neurons, were stimulated in this study. Glycinergic IPSCs could not be elicited when from more superficial sites or when the stimulating electrode was moved to more ventral regions of the dorsal horn (deeper in laminae IV and V). Electrodes were placed in the dorsal root entry zone to stimulate eEPSCs. All eIPSCs were recorded in CNQX (10 μM), AP5 (100 μM) and picrotoxin (80 μM). All eEPSCs were recorded in CNQX (10 μM), picrotoxin (80 μM) and strychnine (0.5 μM). IPSC and EPSC decay constants were determined using the fit exponential tool in Axograph X to fit the current from an average of 10 consecutive IPSCs for each condition. For eIPSCs, a monoexponential function was fitted using a simplex algorithm. For eEPSCs, the decay course was fitted to a double exponential function: f(t) = A 1 e(Àt/τ 1 ) + A 2 e(Àt/τ 2 ), where t is time, A 1 /A 2 are the peak amplitudes of the fast/slow decay components at t = 0 and τ 1 /τ 2 are the fast/slow decay time constants respectively. From this, we calculated the weighted decay time constant (τ w ) defined by τ w = (
. A mono-exponential function was fitted using a simplex algorithm. Drugs were superfused onto slices at a rate of 2 mL·min À1 in normal oxygenated ACSF at 34°C and continued until a stable response was achieved, which was followed by 10 consecutive measurements that were averaged for each data point. Vehicle (DMSO) controls were done for each concentration. Experimental drugs and controls were blinded to the experimenter. At the conclusion of each experiment, strychnine (0.5 μM) or AP5 (100 μM) was added to the superfusion solution to confirm that recorded currents were glycine-mediated IPSCs or NMDA-mediated EPSCs respectively. Tonic current was calculated as the change in holding current following glycine receptor inhibition with strychnine (0.5 μM). Charge transfer of eIPSCs was determined by measuring the amplitude area using the AxoGraph measure function. The tonic current value (taken just before each eIPSC) was subtracted prior to calculating charge transfer to isolate the eIPSC charge without the tonic current component.
Data analysis
Drug effects were normalized and expressed as % of baseline and presented as mean ± SEM. Data were analysed using Prism 6 (version 6.03). Statistics were performed on data before it was normalized, and normal distributions were confirmed using Prism software. Data are normalized in histograms because the amplitude of evoked currents varies significantly in between recordings. Comparisons of two treatments in the same group were made using a two-tailed paired t-test. When multiple comparisons were tested, ANOVA with Sidak's or Fisher's least significant difference post hoc test to correct for multiple comparisons was used, unless otherwise stated in the figure legends. Significance threshold was set at * P < 0.05. Post hoc tests were only applied if ANOVA achieved significance. Group sizes were a minimum of five independent values, which is a number determined from previous studies. Data sets were blinded to the experimenter for analyses. Data points were excluded if the baselines were unstable or if the resistance changed before the experiment concluded, which has resulted in different group numbers for some experiments. The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) .
Materials
Picrotoxin, CNQX, NFPS, ORG25543 and strychnine were purchased from Sigma (Sigma-Aldrich Pty Ltd., Sydney, NSW, Australia). QX-314 was purchased from Alomone Labs (Jerusalem, Israel). AP5 was purchased from Tocris Bioscience (Bristol, UK). All other chemicals were purchased from Sigma (Australia), unless otherwise stated in the text. C18 cis ω8 glycine and C16 cis ω3 glycine were synthesized at the Faculty of Science, the University of Technology Sydney. The structural identity and purity of synthesized compounds was determined by 1 H and 13 C NMR, HRMS and elemental analysis.
Stocks of lipids were made in DMSO.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b) .
Results
Lipid GlyT2 inhibitors increase glycinergic tone and synaptic release onto lamina II interneurons
Basal glycinergic tonic currents and electrically stimulated IPSCs were recorded from lamina II interneurons in wholecell patch, voltage clamp configuration in parasagittal spinal cord slices. Stimulating electrodes were placed in lamina III, and the glycinergic component of the current was recorded in the presence of glutamatergic and GABAergic inhibitors CNQX (10 μM), AP5 (100 μM) and picrotoxin (80 μM). We have previously published data to show that picrotoxin has the same activity as bicuculline on inhibitory currents in spinal cord slices in the concentrations used (Imlach et al., 2016) . The change in holding current in response to GlyT2 inhibitors was considered to be a tonic current mediated by extrasynaptic glycine receptors. Tonic current was calculated as the difference between baseline holding current before and after superfusion of the glycine receptor antagonist strychnine (0.5 μM), which was applied at the conclusion of the experiment (Figure 1) . We investigated the effect of lipid inhibitors (0.1-100 μM) on glycinergic tonic current and found significant increases with all inhibitors except C18 cis ω8 glycine, at concentrations equal or greater than 1 μM (Figure 1 ). The compound that gave the largest significant increase in tonic and evoked currents was NOGly with 35.86 ± 10.2 and 30.7 ± 9.7% increase respectively. OL-Carn (10 μM) increased tonic current by 10.9 ± 3.2% and evoked current by 14.6 ± 5.1%, and C16 cis ω3 (10 μM) increased tonic current by 20.4% ± 4.6% and evoked current by 35.7 ± 4.7%. The effects were dose dependent for NOGly over the four concentrations, but with OL-Carn and C16 cis ω3, the effect on evoked release was only dose dependent up until 10 μM, after which the effects declined. This suggests that these drugs may have different activity at the transporter at higher concentrations, or there may be off target effects that influence the glycinergic current amplitude. We did not test responses above 100 μM as this was the limit of solubility for these compounds, and experiments that followed were performed at 10 μM. Our results showed that C18 cis ω8 (10 μM) increased tonic and evoked glycine currents by 13.2 ± 4.7 and 27.5 ± 17.7%, respectively, but results were not significantly different to pre-drug levels. Mean baseline eIPSC amplitudes for OL-Carn experiments were 246 ± 30 pA, NOGly were 258 ± 54 pA, C16 cis ω3 glycine were 191 ± 25 pA and C18 cis ω8 were 238 ± 32 pA. Vehicle (DMSO) controls showed no significant differences in tonic or evoked IPSC amplitudes when compared with baseline (n = 5).
We have previously found that these compounds have no detectable effect on GlyT1 expressed in oocytes (Mostyn et al., 2017;  Table 1 ). To rule out any alternative modes of action, including activity at the glycine receptor, we performed GlyT2 inhibitors increase spinal glycinergic signalling occlusion experiments in lamina II neurons where slices were incubated with the GlyT2 inhibitor ORG25543 prior and during application of NOGly (Figure 2 ). There was no significant difference in tonic or evoked current amplitude in the presence ORG25543 and ORG25543 with NOGly. ORG25543 increased tonic current amplitude by 36.4 ± 18.1%, and NOGly in the presence of ORG25543 resulted in a tonic current of 49.1 ± 30.1% over baseline (n = 5). ORG25543 increased evoked current amplitude by 24.5 ± 4.5%, and NOGly in the presence of ORG25543 resulted in an evoked current amplitude over baseline of 22.4 ± 7.5% (n = 5).
Effect of lipid GlyT2 inhibitors on decay time and charge transfer of evoked glycinergic IPSCs
It has been previously shown that the GlyT2 inhibitors NAG and ALX-1393 increase the decay time of electrically evoked glycinergic IPSCs due to increased synaptic glycine (Jeong et al., 2010) . To determine whether the GlyT2 inhibitors used in this study prolong the glycinergic eIPSC decay in lamina II neurons, we fitted exponentials to the decay phase of the current traces of experiments shown in Figure 1 . In contrast to previously reported data for NAG and ALX-1393, we found that in most cases, there was no change in decay time, with the exception of 10 μM C16 cis ω3 glycine, which caused a 28.3 ± 6.7% increase compared with pre-drug decay time (Figure 3 ). To further investigate this lack of effect on decay time constant, we assessed the effects of 10 μM NOGly on spontaneous mIPSC activity (Figure 4) . We observed no change in either amplitude or decay in the presence of NOGly (n = 7).
Charge transfer was calculated on all eIPSCs with holding current subtracted. No changes were seen with any inhibitors at 0.1 μM, but data showed increases in charge transfer with OL-Carn and C16 cis ω3 glycine at higher concentrations. As a percentage of baseline, OL-Carn increased charge transfer with values of 123 ± 7, 123 ± 3 and 124 ± 8% for 1, 10 and 100 μM respectively (P < 0.05, paired t-tests on raw data). NOGly gave no significant change in charge compared with baseline with mean values of 94 ± 17, 111 ± 20 and
Figure 2
NOGly does not increase glycinergic tonic current further in the presence of the GlyT2 inhibitor ORG25543. (A) Time plot showing tonic glycinergic tonic current amplitude with baseline (black), followed by 5 μM ORG25543 (grey), 10 μM NOGly (red) and 0.5 μM strychnine (black). (B) Histograms show glycinergic tonic current normalized to baseline and shown as a percentage. Data are expressed as mean ± SEM, n = 5.
Figure 3
The effect of GlyT2 inhibitors on the decay time of glycinergic eIPSCs. The effect of GlyT2 inhibitors (0.1-100 μM) on the decay time of evoked IPSCs in lamina II neurons was measured by fitting exponentials to the decay phase of the current traces. Histograms show glycinergic current decay times normalized to baseline and shown as a percentage. Examples of glycine-mediated eIPSC traces are shown for baseline controls (grey) and in the presence of 10 μM GlyT2 inhibitor (coloured) for each drug, scaled to baseline amplitude, and with strychnine inhibition of glycine receptors, not scaled. N is shown in white text. Normalized data are presented as mean ± SEM. Scale bars are 25 ms.
* P < 0.05 (paired t-test).
102 ± 10% for 1, 10 and 100 μM respectively. C16 cis ω3 glycine gave mean values of charge transfer compared with baseline of 106 ± 19, 138 ± 25 and 133 ± 23% (P > 0.05, <0.05, >0.05, paired t-tests on raw data) for 1, 10 and 100 μM respectively. C18 cis ω8 glycine did not change the average charge transfer significantly with mean values compared with baseline of 97 ± 5, 109 ± 13 and 105 ± 9 for 1, 10 and 100 μM respectively.
Lipid GlyT2 inhibitors do not deplete glycine from presynaptic vesicles following prolonged exposure
Irreversible inhibitors of GlyT2 such as ORG25543 have been shown to decrease presynaptic glycine vesicle recycling to a level that does not support synaptic signalling (Gomeza et al., 2003) . The compounds used in this study are partial inhibitors, so they are more likely to allow sufficient reuptake, which would support glycinergic inhibition in the presence of the drug. To investigate vesicle depletion after prolonged exposure to GlyT2 inhibitors, we compared mIPSC amplitude, frequency and decay prior to drug application and then after 10 min and 2 h exposure to 10 μM of each drug. All mIPSCs during the 10 min period were analysed. We compared the effects of ORG25543 (5 μM) on mIPSC characteristics over these time periods. Frequency of mIPSCs was not significantly different following 10 min of exposure for OL-Carn (93.7 ± 21.2% compared with baseline), NOGly (115.9 ± 27.2%), C18 cis ω8 glycine (95.6 ± 8.7%) and C16 cis ω3 glycine (110.3 ± 14.3%), while ORG25543 mIPSC frequency was significantly reduced (51.6 ± 9.9% of baseline, P < 0.05). Following 120 min incubation with drug, mIPSC frequencies were not significantly different from the vehicle (DMSO) control for OL-Carn (66.9 ± 22.1% compared with control), NOGly (104.79 ± 43.4%), C18 cis ω8 glycine (84.4 ± 16.8%) and C16 cis ω3 glycine (109.9 ± 23.5%), while ORG25543 was again significantly reduced (8.2 ± 1.4% compared with baseline, P < 0.05). Data for mIPSC frequency before normalization at 10 min were as follows: OL-Carn: 1.05 ± 0.66 Hz for baseline and 1.14 ± 0.67 Hz for drug, NOGly: 0.29 ± 0.10 Hz for baseline and 0.3 ± 0.18 Hz for drug, C18 cis ω8 glycine: 0.35 ± 0.13 Hz for baseline and 0.32 ± 0.11 Hz for drug, C16 cis ω3 glycine: 0.92 ± 0.31 Hz for control and 0.92 ± 0.22 Hz for drug and ORG25543 was 0.45 ± 0.21 Hz for control and 0.19 ± 0.06 Hz for drug. Following 120 min incubation with drug, the mIPSC frequency of the DMSO control was 0.56 ± 0.15 Hz, OL-Carn was 0.43 ± 0.11 Hz, NOGly was 0.80 ± 0.25 Hz, C18 cis ω8 glycine was 0.54 ± 0.12 Hz, C16 cis ω3 glycine was 0.73 ± 0.18 Hz and ORG25543 was 0.05 ± 0.01 Hz. Amplitude of mIPSCs was not significantly different to baseline following 10 min of exposure of OL-Carn (amplitudes were 97.0 ± 9.7% of baseline), NOGly (92.5 ± 15.0%), C18 cis ω8 glycine (104.3 ± 5.4%), C16 cis ω3 glycine (83.9 ± 4.8%) and ORG25543 (97.8 ± 12.8%). Following 120 min incubation with drug, mIPSC amplitudes were not significantly different to the vehicle (DMSO) control for OL-Carn (amplitudes were 66.1 ± 5.6% compared with control), NOGly (84.8 ± 12.2%), C18 cis ω8 glycine (105.8 ± 10.1%), C16 cis ω3 glycine (93.3 ± 18.7%) and ORG25543 (68.4 ± 9.7%). Data for mIPSC amplitude before
Figure 4
Lipid GlyT2 inhibitors have no effect on mIPSC amplitude or decay and do not deplete synaptic vesicle refilling after prolonged exposure. (A) Traces show mIPSC events prior to exposure to 10 μM OLCarn, NOGly, C18 cis ω8 Gly, C16 cis ω3 Gly and 5 μM ORG25543 and post-exposure at 10 and 120 min. All mIPSC activity was inhibited by strychnine. normalization at 10 min were as follows: OL-Carn: 52.8 ± 11.4 pA for baseline and 44.6 ± 11.9 pA for drug, NOGly: 28.2 ± 2.8 pA for baseline and 27.1 ± 3.7 pA for drug, C18 cis ω8 glycine: 40.3 ± 4.9 pA for baseline and 41.7 ± 5.2 pA for drug, C16 cis ω3 glycine: 62.3 ± 9.1 pA for control and 50.8 ± 5.1 pA for drug and ORG25543 was 41.2 ± 1.9 pA for control and 40.8 ± 6.4 pA for drug. Following 120 min incubation with drug, the mIPSC amplitude of the DMSO control was 44.3 ± 3.8 pA, OL-Carn was 29.3 ± 2.5 pA, NOGly was 36.7 ± 3.7 pA, C18 cis ω8 glycine was 46.9 ± 4.9 pA, C16 cis ω3 glycine was 41.4 ± 7.7 pA and ORG25543 was 30.3 ± 4.0 pA. Decay times of mIPSCs were not significantly different to baseline following 10 min of exposure of OL-Carn (normalized decay time was 90.0 ± 13.8% compared with baseline), NOGly (102.4 ± 15.7%), C18 cis ω8 glycine (101.3 ± 11.3%) and C16 cis ω3 glycine (97.7 ± 8.5%), while the mIPSC decay time for ORG25543 was significantly increased (154.8 ± 16.1%, P < 0.05). Following 120 min incubation with drug, mIPSC decay rates were not significantly different to the vehicle (DMSO) control for OL-Carn (normalized decay time was 102.7 ± 11.4% compared with control), NOGly (84.18 ± 15.1%), C18 cis ω8 glycine (109.3 ± 14.0%), C16 cis ω3 glycine (88.1 ± 13.1%) and ORG25543 (112.0 ± 18.3%). Data for mIPSC decay before normalization at 10 min were as follows: OL-Carn: 4.4 ± 0.6 ms for baseline and 4.1 ± 0.5 ms for drug, NOGly: 4.1 ± 0.4 ms for baseline and 3.4 ± 0.3 ms for drug, C18 cis ω8 glycine: 4.8 ± 0.7 ms for baseline and 4.7 ± 0.5 ms for drug, C16 cis ω3 glycine: 5.6 ± 1.2 ms for control and 5.1 ± 0.6 ms for drug and ORG25543 was 3.9 ± 0.4 ms for control and 5.8 ± 0.3 ms for drug. Following 120 min incubation with drug, the mIPSC decay of the DMSO control was 4.4 ± 0.6 ms, OL-Carn was 4.5 ± 0.5 ms, NOGly was 3.9 ± 0.5 ms, C18 cis ω8 glycine was 4.8 ± 0.7 ms, C16 cis ω3 glycine was 3.9 ± 0.5 ms and ORG25543 was 4.9 ± 0.7 ms.
Excitatory NMDA-mediated currents are not affected by the lipid inhibitors
At excitatory synapses, glycine acts as a co-activator for NMDA receptor-mediated synaptic transmission. During periods of high presynaptic activity in the dorsal horn, glycine released from inhibitory interneurons can escape the synaptic cleft and activate NMDA receptors in the area, which is referred to as spillover (Ahmadi et al., 2003) . Increasing synaptic glycine by inhibition of GlyT2 at inhibitory synapses may increase the chance of enhanced NMDA activity at excitatory synapses if the spillover is sufficient, which is undesirable as it would have a proalgesic effect. Inhibition of GlyT1 has previously been shown to increase the amplitude of evoked NMDA-mediated EPSCs through the activity of this transporter at excitatory synapses (Raiteri and Raiteri, 2010) . In this study, lipid inhibitors were applied in the presence of the CNQX (10 μM), picrotoxin (80 μM) and strychnine (0.5 μM) to block AMPA-, GABA-and glycinemediated synaptic currents, and EPSCs were elicited by dorsal rootlet stimulation while holding lamina II neurons at À40 mV to prevent voltage-dependent block by endogenous Mg 2+ . A study by Lester et al. (1989) found that CNQX antagonizes the binding site of NMDA receptors in a crude membrane preparation for guinea pig cortex. However, more recent studies have demonstrated that CNQX (10 μM) does not inhibit potentiation of NMDA-mediated eEPSCs by exogenously applied glycine in spinal cord slices (Bradaia et al., 2004) . To confirm the lack of antagonistic activity of CNQX at the glycine binding site of NMDA receptors in our experiments, we performed control experiments under the same conditions with dichlorokynurenic acid (DCKA), an antagonist of the glycine site of the NMDA receptor. We found that 1 μM DCKA reduced NMDAmediated eEPSCs by 42.7 ± 3.0% in the presence of 10 μM CNQX (n = 5).
Our results show that none of the GlyT2 inhibitors used in this study significantly increased the amplitude or decay time constant of NMDA-mediated eEPSCs ( Figure 5 ). To strengthen these findings, we also performed control experiments using the GlyT1 inhibitor, NFPS (3 μM). Studies by other groups have shown that this inhibitor increases amplitude (Jeong et al., 2010) and decay (Oyama et al., 2017) of NMDA-mediated synaptic currents. Our results showed that NMDA current amplitude increased from 57 ± 6 pA at baseline to 65 ± 7 pA with NFPS (P < 0.05, n = 5, Figure 5A ), and mean time constants were 140 ± 26 ms at baseline and 179 ± 43 ms in the presence of NFPS (P < 0.05, n = 5, Figure 5B ).
Discussion
The aim of this study was to investigate the effect of lipid inhibitors of GlyT2 on synaptic transmission at inhibitory and excitatory synapses within the dorsal horn. Oocyte studies show similar GlyT2 IC 50 values for the four compounds tested, which range from 0.32 to 0.81 μM (Wiles et al., 2006; Carland et al., 2013; Mostyn et al., 2017) . In the dorsal horn, all compounds also had similar effects on glycinergic transmission, which is likely to be due to the small differences in GlyT2 IC 50 . We show that the lipids with glycine head groups retain the effects on inhibitory transmission of the less reversible OL-Carn, which has a carnitine head group. NOGly, which has the same tail as OL-Carn, gave maximal increases of 35.86 ± 10.2 and 30.7 ± 9.7% for tonic and eIPSC amplitudes, while OL-Carn increased tonic current by 21.9 ± 5.2 and eIPSC amplitude by 22.6 ± 10.3. Increased synaptic glycine has been previously shown to increase decay time constant of eIPSCs. ORG25543 and ALX1393 increase both glycinergic tonic currents and the decay time of eIPSCs in spinal cord slices (Bradaia et al., 2004; Oyama et al., 2017) . In the current study, we found that only one of the lipid GlyT2 inhibitors, C16 cis ω3 glycine, caused a significant increase in decay time, which only occurred at a concentration of 10 μM. Since the size of the eIPSCs response can mask more subtle effects on decay, we also compared the time constants of spontaneous mIPSC events following an incubation in NOGly. These data showed no difference in mIPSC kinetics or amplitude, which supports the results we obtained when analysing eIPSC events. Interestingly, the increased delay we observed in C16 cis ω3 glycine eIPSCs was also reflected in the eIPSC charge transfer in response to 10 μM C16 cis ω3 glycine, which was significantly increased. OL-Carn also produced significant increases in eIPSC charge transfer at concentrations between 1 and 100 μM, which may be due to its longer lasting activity since it is a less reversible compound. The general lack of effect on both eIPSC decay and charge transfer would suggest that these glycine head group partial inhibitors are much less effective on GlyT2 than previously described inhibitors of GlyT2 and GlyT1. Although they are still able to increase synaptic glycine, they may not be as effective at allowing glycine to accumulate, which is required to activate synaptic and extrasynaptic receptors that slow the decay kinetics of synaptic currents (Oyama et al., 2017) . Our data showing no spillover to NMDA receptors in the presence of these drugs supports this idea. This could be a result of the partial inhibitory effects of these lipid inhibitors, which differ to ORG25543 and ALX1393, which are irreversible and complete inhibitors respectively. To rule out any alternative modes of action, including activity at the glycine receptor and GlyT1, we performed an occlusion experiment where slices were incubated with ORG25543 prior and during application of NOGly. These results showed no additional increase in glycinergic transmission with NOGly, which suggests there is no potentiation of the glycine receptor. This differs to the structurally similar compound NAGly, which has also been shown to act as an allosteric modulator of glycine receptors, with potentiation of α1, and inhibition of α2 and α3 glycine receptors (Yévenes and Zeilhofer, 2011) .
It has been previously shown that irreversible inhibitors of GlyT2 such as ORG25543 can decrease glycinergic signalling due to reduced vesicle recycling. Following an initial increase in glycinergic activity, irreversible inhibitors can cause a reduction in glycinergic eIPSCs in vitro suggesting that the presynaptic glycine vesicle recycling is reduced to a level that does not support synaptic signalling (Gomeza et al., 2003) . A recent study by Oyama et al. (2017) showed that the IPSC amplitudes are significantly reduced following high-frequency stimulation (3 min) in the presence of the GlyT2 inhibitor ALX1393. This provides further evidence that GlyT2 plays an essential role in glycine vesicle refilling. Their experiments using NFPS show that inhibition of GlyT1, which is not expressed on inhibitory terminals, does not reduce glycine IPSC amplitude but still prolongs the IPSC decay phase. To test the effect of lipid GlyT2 inhibitors on rundown, we measured mIPSC amplitude, frequency and decay following a 2 h incubation with 10 μM of each lipid GlyT2 inhibitor or 5 μM of ORG25543. We found no change in amplitude, frequency or decay following incubation with the GlyT2 lipid inhibitors, which suggests these compounds do not reduce vesicle recycling. However, we did observe a significant reductions in mIPSC frequency after 10 min and 2 h incubation with ORG25543, which suggests this compound causes significant vesicle depletion. Decay rate of mIPSCs was significantly increased following 10 min exposure to ORG25543 but not after 2 h. This may be due to prolonged rundown resulting in a decrease in synaptic glycine build up.
To investigate whether these lipid inhibitors increased glycine-mediated excitatory activity in the dorsal horn, we measured their effect on NMDA-mediated currents. For these experiments, we used one concentration of drug (10 μM) that we found to be effective at increasing glycinergic tone in the first set of experiments. At excitatory synapses, glycine acts as a co-activator for NMDA receptor-mediated synaptic transmission. Increased glycine at these synapses may result from decreased GlyT2 activity and spillover to excitatory synapses or decreased activity of GlyT1, which is involved in glycine transport at excitatory synapses. In this study, we found that none of the lipid inhibitors increased eEPSC amplitude or decay of NMDA-mediated eEPSCs. This differed to the effect of the GlyT1 inhibitor, NFPS, which significantly increased amplitude and decay. These results suggests that spillover of glycine from inhibitory synapses is not induced by these GlyT2 inhibitors and the compounds tested have no effect on GlyT1. These are desirable properties, since NMDA activation is likely to exacerbate pain symptoms by increasing excitation and spinal sensitization (Mingorance-Le Meur et al., 2013) .
Modifications in tail length and double-bond position with the glycine head group drugs had no significant difference in activity across concentrations. Although these structural changes have the potential to cause subtle differences in activity, none of these modifications abolish or greatly increase activity. This would suggest these compounds may have similar potencies in vivo, but this is yet to be tested in animal pain models.
In conclusion, we showed that three of the four lipid inhibitors of GlyT2 are effective at increasing glycinergic neurotransmission in the dorsal horn and neurotransmission is increased by all compounds, except for C18 cis ω8 glycine, with specific activity at inhibitory synapses and not at excitatory synapses (Figure 6 ). The lack of significant effect of C18 cis ω8 glycine may be because it has the lowest maximal inhibitory effect on GlyT2 of these compounds, with a maximal inhibition of 61.3 ± 1.69% (Table 1) . There is a great need for new therapeutics to treat chronic pain conditions, and targeting glycinergic signalling in the spinal cord is a promising strategy. In neuropathic and inflammatory pain conditions, glycinergic signalling is greatly reduced, and increasing signalling through glycine receptors in the dorsal horn has antinociceptive effects. Due to relatively localized expression of GlyT2 in the spinal cord, these drugs are likely to have good side effect profiles. Therefore, the GlyT2 inhibitors used in this study have potential as pain therapeutics.
Figure 6
Nociceptive signalling can be reduced by increasing glycinergic activity in the spinal cord dorsal horn through inhibition of the GlyT2, which increases inhibitory signalling through glycine receptors (GlyRs). Since glycine is a co-activator of excitatory NMDA receptors (NMDARs), it is important that the increased glycine does not spillover into the excitatory synapses as this may have proalgesic effects.
